Table 1 Differences between demographic and clinical characteristics of survivor and death group.
From: A prediction nomogram for mortality in patients following wasp stings: a retrospective study
Variables | Total (N = 486) | Survivor (N = 435) | Death (N = 51) | P |
|---|---|---|---|---|
Gender, n (%) | 0.649 | |||
Female | 200 (41.2%) | 177 (40.7%) | 23 (45.1%) | |
Male | 286 (58.8%) | 258 (59.3%) | 28 (54.9%) | |
Age ≥ 65, n (%) | < 0.001 | |||
No | 397 (81.7%) | 366 (84.1%) | 31 (60.8%) | |
Yes | 89 (18.3%) | 69 (15.9%) | 20 (39.2%) | |
Number of stings < 25, n (%) | < 0.001 | |||
No | 186 (38.3%) | 140 (32.2%) | 46 (90.2%) | |
Yes | 300 (61.7%) | 295 (67.8%) | 5 (9.80%) | |
Number of stings 25–50, n (%) | 1.000 | |||
No | 362 (74.5%) | 324 (74.5%) | 38 (74.5%) | |
Yes | 124 (25.5%) | 111 (25.5%) | 13 (25.5%) | |
Number of stings ≥ 50, n (%) | < 0.001 | |||
No | 424 (87.2%) | 406 (93.3%) | 18 (35.3%) | |
Yes | 62 (12.8%) | 29 (6.67%) | 33 (64.7%) | |
Hematuria, n (%) | < 0.001 | |||
No | 331 (68.1%) | 328 (75.4%) | 3 (5.88%) | |
Yes | 155 (31.9%) | 107 (24.6%) | 48 (94.1%) | |
Hemolysis, n (%) | < 0.001 | |||
No | 271 (55.8%) | 270 (62.1%) | 1 (1.96%) | |
Yes | 215 (44.2%) | 165 (37.9%) | 50 (98.0%) | |
IMV (24 h), n (%) | < 0.001 | |||
No | 423 (87.0%) | 416 (95.6%) | 7 (13.7%) | |
Yes | 63 (13.0%) | 19 (4.37%) | 44 (86.3%) | |
Hemo Purification, n (%) | < 0.001 | |||
No | 374 (77.0%) | 362 (83.2%) | 12 (23.5%) | |
Yes | 112 (23.0%) | 73 (16.8%) | 39 (76.5%) | |
AST ≥ 120U/L, n (%) | < 0.001 | |||
No | 338 (69.5%) | 332 (76.3%) | 6 (11.8%) | |
Yes | 148 (30.5%) | 103 (23.7%) | 45 (88.2%) | |
APTT ≥ 90 s, n (%) | < 0.001 | |||
No | 370 (76.1%) | 359 (82.5%) | 11 (21.6%) | |
Yes | 116 (23.9%) | 76 (17.5%) | 40 (78.4%) | |
CK ≥ 1000U/L, n (%) | < 0.001 | |||
No | 348 (71.6%) | 339 (77.9%) | 9 (17.6%) | |
Yes | 138 (28.4%) | 96 (22.1%) | 42 (82.4%) | |
LDH ≥ 2200U/L, n (%) | < 0.001 | |||
No | 421 (86.6%) | 405 (93.1%) | 16 (31.4%) | |
Yes | 65 (13.4%) | 30 (6.90%) | 35 (68.6%) | |
WBC (109/L), median (Q1, Q3) | 14.5 [10.2;20.5] | 13.8 [9.86;19.1] | 22.2 [18.9;32.0] | < 0.001 |
Hb (g/L), median (Q1, Q3) | 133 [120;147] | 134 [121;148] | 120 [108;138] | < 0.001 |
RBC (1012/L), median (Q1, Q3) | 4.32 [3.86;4.74] | 4.38 [3.96;4.76] | 3.77 [3.33;4.22] | < 0.001 |
PLT (109/L), median (Q1, Q3) | 204 [157;247] | 204 [160;244] | 188 [124;300] | 0.973 |
T-Bil (μmol/L), median (Q1, Q3) | 22.5 [14.3;52.0] | 20.6 [13.3;43.0] | 84.4 [53.1;129] | < 0.001 |
Cr (μmol/L), median (Q1, Q3) | 80.4 [68.3;102] | 77.8 [66.4;93.9] | 168 [114;254] | < 0.001 |
Chronic Liver Insufficiency, n (%) | 1.000 | |||
No | 473 (97.3%) | 423 (97.2%) | 50 (98.0%) | |
Yes | 13 (2.67%) | 12 (2.76%) | 1 (1.96%) | |
Chronic Rrenal Insuiciency, n (%) | 1.000 | |||
No | 485 (99.8%) | 434 (99.8%) | 51 (100%) | |
Yes | 1 (0.21%) | 1 (0.23%) | 0 (0.00%) | |
Chronic Respiratory Disease, n (%) | 0.364 | |||
No | 474 (97.5%) | 425 (97.7%) | 49 (96.1%) | |
Yes | 12 (2.47%) | 10 (2.30%) | 2 (3.92%) | |
Cerebral Vascular Disease, n (%) | 0.242 | |||
No | 477 (98.1%) | 428 (98.4%) | 49 (96.1%) | |
Yes | 9 (1.85%) | 7 (1.61%) | 2 (3.92%) | |
Hypertensive, n (%) | 0.534 | |||
No | 410 (84.4%) | 369 (84.8%) | 41 (80.4%) | |
Yes | 76 (15.6%) | 66 (15.2%) | 10 (19.6%) | |
Cardiovascular Disease, n (%) | 0.176 | |||
No | 460 (94.7%) | 414 (95.2%) | 46 (90.2%) | |
Yes | 26 (5.35%) | 21 (4.83%) | 5 (9.80%) | |
Diabetes, n (%) | 1.000 | |||
No | 471 (96.9%) | 421 (96.8%) | 50 (98.0%) | |
Yes | 15 (3.09%) | 14 (3.22%) | 1 (1.96%) |
